Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Rexahn Pharmaceuticals (RNN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,590
  • Shares Outstanding, K 48,283
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,370 K
  • 60-Month Beta 0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.49
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.11
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.50 +6.00%
on 03/01/19
0.59 -10.17%
on 03/08/19
-0.01 (-0.93%)
since 02/22/19
3-Month
0.50 +6.00%
on 03/01/19
1.65 -67.88%
on 01/18/19
-0.50 (-48.54%)
since 12/21/18
52-Week
0.50 +6.00%
on 03/01/19
2.38 -77.73%
on 05/21/18
-1.10 (-67.48%)
since 03/22/18

Most Recent Stories

More News
Rexahn Pharmaceuticals Reports 2018 Financial Results

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced...

RNN : 0.53 (-2.91%)
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE(R) in First-line Metastatic Pancreatic Cancer Patients

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced...

RNN : 0.53 (-2.91%)
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced...

RNN : 0.53 (-2.91%)
Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, presented...

RNN : 0.53 (-2.91%)
Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced...

RNN : 0.53 (-2.91%)
Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced...

RNN : 0.53 (-2.91%)
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow

FinancialBuzz.com News Commentary

RNN : 0.53 (-2.91%)
OGEN : 0.62 (+1.64%)
ONCS : 0.50 (-4.91%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0106 (-4.50%)
SNSS : 1.25 (+30.21%)
Rexahn Announces Pricing of Public Offering of Common Stock and Warrants

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced the pricing of an underwritten public offering of 10,750,000 shares of its common stock and warrants to purchase up to 10,750,000 shares...

RNN : 0.53 (-2.91%)
Rexahn Announces Proposed Public Offering of Common Stock and Warrants

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public...

RNN : 0.53 (-2.91%)
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, presented...

RNN : 0.53 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RNN with:

Business Summary

REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat...

See More

Key Turning Points

2nd Resistance Point 0.56
1st Resistance Point 0.55
Last Price 0.53
1st Support Level 0.52
2nd Support Level 0.50

See More

52-Week High 2.38
Fibonacci 61.8% 1.66
Fibonacci 50% 1.44
Fibonacci 38.2% 1.22
Last Price 0.53
52-Week Low 0.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar